文献速递妇科

醋酸乌利司他治疗症状性子宫平滑肌瘤:一项随机对照试验

Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2018-01-01

这项3期双盲安慰剂对照试验纳入157例绝经前症状性子宫平滑肌瘤女性,随机接受5 mg或10 mg醋酸乌利司他或安慰剂每日一次治疗12周。两种剂量组的闭经率均显著高于安慰剂,闭经时间更短,生活质量改善更明显,且耐受性良好。

要点

  • 5 mg和10 mg醋酸乌利司他组闭经率分别为47.2%和58.3%,均显著高于安慰剂的1.8%(均P<.001)。
  • 两种剂量醋酸乌利司他的闭经时间均短于安慰剂(P<.001),生活质量改善也均优于安慰剂(P<.001)。
  • 常见不良事件为高血压、肌酸磷酸激酶升高和潮热,严重不良事件4例但均认为与治疗无关,子宫内膜活检均为良性。

核心结论

  • 5 mg和10 mg醋酸乌利司他耐受性良好,在症状性子宫平滑肌瘤女性的闭经率和闭经时间方面均优于安慰剂。

研究设计与样本

  • 这是一项3期、双盲、安慰剂对照研究,纳入18-50岁绝经前女性,要求有异常子宫出血、一个或多个离散平滑肌瘤且子宫大小不超过妊娠20周。
  • 患者按1:1:1随机接受5 mg醋酸乌利司他、10 mg醋酸乌利司他或安慰剂每日一次治疗12周,随后12周无药随访。
  • 计划样本量为150例,以分别比较每种醋酸乌利司他剂量与安慰剂;实际从2014年3月至2016年3月随机了157例患者。

主要发现

  • 5 mg组53例中25例(47.2%[97.5%CI 31.6-63.2])和10 mg组48例中28例(58.3%[97.5%CI 41.2-74.1])达到闭经,安慰剂组56例中1例(1.8%[97.5%CI 0.0-10.9])达到闭经(均P<.001)。
  • 两种醋酸乌利司他剂量的闭经时间均短于安慰剂(P<.001),且两种剂量在生活质量改善方面均优于安慰剂(P<.001)。
  • 治疗期间任一醋酸乌利司他组发生率≥5%的常见不良事件为高血压、血肌酸磷酸激酶升高和潮热;4例患者发生严重不良事件,但均认为与治疗无关;子宫内膜活检均为良性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of symptomatic uterine leiomyomas. METHODS: This phase 3, double-blind, placebo-controlled study enrolled premenopausal women (aged 18-50 years) with abnormal uterine bleeding, one or more discrete leiomyomas, and uterine size 20 weeks of gestation or less. Patients were randomized 1:1:1 to 5 mg ulipristal, 10 mg ulipristal, or placebo once daily for 12 weeks followed by 12-week drug-free follow-up. Coprimary endpoints were rate of and time to amenorrhea, defined as no bleeding for the last 35 consecutive days of treatment. Secondary endpoints included rates of amenorrhea from day 11 and change from baseline to endpoint in the Revised Activities subscale of the Uterine Fibroid Symptom and Quality of Life questionnaire, which includes questions pertaining to physical and social activities. Safety assessments included adverse event monitoring and endometrial biopsies. A sample size of 150 was planned to compare separately each dose of ulipristal with placebo. RESULTS: From March 2014 to March 2016, 157 patients were randomized. Demographics were similar across treatment groups. Amenorrhea was achieved by 25 of 53 (47.2% [97.5% CI 31.6-63.2]) and 28 of 48 (58.3% [97.5% CI 41.2-74.1]) patients treated with 5 mg and 10 mg ulipristal, respectively, compared with 1 of 56 (1.8% [97.5% CI 0.0-10.9]) placebo-treated patients (both P<.001). Time to amenorrhea was shorter for both ulipristal doses compared with placebo (P<.001), and both doses of ulipristal resulted in improved quality of life compared with placebo (P<.001). Common adverse events (5% or greater in either ulipristal group during treatment) were hypertension, elevated blood creatinine phosphokinase, and hot flushes. Serious adverse events occurred in four patients, but none was considered related to treatment. Endometrial biopsies were benign. CONCLUSION: Ulipristal at 5 mg and 10 mg were well tolerated and superior to placebo in rate of and time to amenorrhea in women with symptomatic uterine leiomyomas. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov number, NCT02147197.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Simon JA, Catherino W, Segars JH, et al. Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018. PMID: 29420395. doi:10.1097/AOG.0000000000002462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。